2025
P0442 Prevalence and Impact of E-cigarettes on Disease Outcomes in Patients with Inflammatory Bowel Disease
Almuhaya H, Alashkar R, Alsebaai D, Albadawi N, Almutairdi A, Attamimi M, Desai S, Al-Bawardy B. P0442 Prevalence and Impact of E-cigarettes on Disease Outcomes in Patients with Inflammatory Bowel Disease. Journal Of Crohn's And Colitis 2025, 19: i951-i951. DOI: 10.1093/ecco-jcc/jjae190.0616.Peer-Reviewed Original ResearchTraditional cigarette smokingPrevalence of EC useClinical outcomesCrohn's diseaseEC useAdvanced therapiesIBD patientsCigarette smokingUlcerative colitisElectronic cigarettesPenetrating diseaseComposite outcomeIBD-unclassifiedHistory of intestinal surgeryAssociated with male sexFollow-up durationImpact of e-cigarettesDiagnosis of IBDCross-sectional studyCigarette smoking historyInflammatory bowel diseaseNo significant differencePerianal diseaseIBD registrySurgical intervention
2024
Fractional flow reserve-guided complete revascularization versus culprit-only percutaneous coronary intervention in patients with myocardial infarction: A meta-analysis of randomized controlled trials
Ezenna C, Krishna M, Joseph M, Pereira V, Ramesh P, Ismayl M, Nanna M, Goldsweig A. Fractional flow reserve-guided complete revascularization versus culprit-only percutaneous coronary intervention in patients with myocardial infarction: A meta-analysis of randomized controlled trials. Cardiovascular Revascularization Medicine 2024 PMID: 39721936, DOI: 10.1016/j.carrev.2024.12.004.Peer-Reviewed Original ResearchContrast-induced acute kidney injuryMultivessel coronary artery diseaseFFR-guided CRCoronary artery diseaseComposite adverse eventsPercutaneous coronary interventionRandomized controlled trialsCardiac deathAdverse eventsMyocardial infarctionComplete revascularizationRecurrent myocardial infarction ratesMedian follow-up durationRisk ratioCoronary interventionStent thrombosisMeta-analysis of randomized controlled trialsControlled trialsFFR-guided complete revascularizationFollow-up durationMeta-analysisAcute kidney injuryAll-cause deathCochrane Central databasesCulprit-only percutaneous coronary interventionElectrochemotherapy in the Locoregional Treatment of Metastatic Colorectal Liver Metastases: A Systematic Review
Barbieri P, Posa A, Lancellotta V, Madoff D, Maresca A, Cornacchione P, Tagliaferri L, Iezzi R. Electrochemotherapy in the Locoregional Treatment of Metastatic Colorectal Liver Metastases: A Systematic Review. Current Oncology 2024, 31: 7403-7413. PMID: 39590176, PMCID: PMC11592455, DOI: 10.3390/curroncol31110546.Peer-Reviewed Original ResearchConceptsCRC liver metastasesLiver metastasesColorectal cancerComplete responseOverall survivalProgressive diseaseInclusion criteriaResection of CRC liver metastasesTreatment of CRC liver metastasisColorectal cancer liver metastasesSystematic searches of PubMedFrequent liver metastasesMedian overall survivalSecondary liver cancerFollow-up durationColorectal Liver MetastasesMultiple risk factorsCancer-related mortalitySearch of PubMedECT-related complicationsEvidence qualityLocoregional treatmentSurgical resectionIdentified articlesGRADE approachTranscatheter versus surgical aortic valve replacement in lower-risk patients: an updated meta-analysis of randomised controlled trials
Reddy R, Howard J, Reardon M, Thyregod H, Jorgensen T, Toff W, Forrest J, Leon M, Ahmad Y. Transcatheter versus surgical aortic valve replacement in lower-risk patients: an updated meta-analysis of randomised controlled trials. European Heart Journal 2024, 45: ehae666.2456. DOI: 10.1093/eurheartj/ehae666.2456.Peer-Reviewed Original ResearchLower-risk patientsIndividual patient dataFollow-upNo significant differenceClinical outcomesPairwise random-effects meta-analysesNew-onset atrial fibrillationLong-term clinical outcomesSurgical aortic valve replacementKaplan-Meier survival curvesMeta-analysis of randomised controlled trialsLow-surgical riskMeta-analysesAortic valve reinterventionReconstructed individual patient dataLow surgical riskAortic valve replacementFollow-up durationSevere aortic stenosisMeta-analysisSignificant differenceCox proportional hazards regressionComposite of deathKaplan-Meier plotsLonger-term follow-upPostacute Sequelae of COVID-19 in Pediatric Patients Within the United States: A Scoping Review
Miller C, Borre C, Green A, Funaro M, Oliveira C, Iwasaki A. Postacute Sequelae of COVID-19 in Pediatric Patients Within the United States: A Scoping Review. American Journal Of Medicine Open 2024, 12: 100078. PMID: 39639960, PMCID: PMC11617896, DOI: 10.1016/j.ajmo.2024.100078.Peer-Reviewed Original ResearchClinical epidemiologyPost-acute sequelae of COVID-19High risk of biasLack of standardized definitionsPost-acute sequelaeRisk of biasSequelae of COVID-19United StatesScoping reviewComprehensive literature searchUS childrenShort follow-up durationFollow-up durationInclusion criteriaFemale sexOlder ageRisk factorsSARS-CoV-2 infectionLiterature searchChest painHigh riskOptimal preventionPediatric patientsPersistent symptomsCOVID-19Prognosis After Withdrawal of Cardioprotective Therapy in Patients With Improved Cancer Therapeutics–Related Cardiac Dysfunction
Park H, Lee N, Hwang C, Cho S, Choi G, Cho J, Yoon H, Kim K, Ahn Y. Prognosis After Withdrawal of Cardioprotective Therapy in Patients With Improved Cancer Therapeutics–Related Cardiac Dysfunction. JACC CardioOncology 2024, 6: 699-710. PMID: 39479323, PMCID: PMC11522502, DOI: 10.1016/j.jaccao.2024.07.018.Peer-Reviewed Original ResearchCancer therapeutics-related cardiac dysfunctionLeft ventricular ejection fractionBaseline left ventricular ejection fractionCardioprotective therapiesCardiac dysfunctionClinical outcomesSingle-center prospective cohort studyMedian follow-up durationVentricular ejection fractionFollow-up durationLong-term prognosisProspective cohort studyEjection fractionEchocardiographic changesHeart failureRetrospective analysisClinical eventsCohort studyPatientsPrognosisDiagnosisTherapyDysfunctionWithdrawalBaselineCirculating Metabolite Profiles and Risk of Coronary Heart Disease Among Racially and Geographically Diverse Populations
Deng K, Gupta D, Shu X, Lipworth L, Zheng W, Cai H, Cai Q, Yu D. Circulating Metabolite Profiles and Risk of Coronary Heart Disease Among Racially and Geographically Diverse Populations. Circulation Genomic And Precision Medicine 2024, 17: e004437. PMID: 38950084, PMCID: PMC11335450, DOI: 10.1161/circgen.123.004437.Peer-Reviewed Original ResearchConceptsMetabolite risk scoreConventional risk factorsCoronary heart diseaseConditional logistic regressionRisk factorsIncident coronary heart diseaseCirculating metabolitesC-indexAssociated with incident coronary heart diseaseCHD casesHeart diseaseCirculating metabolite profilesFollow-up durationBaseline plasma samplesIncident CHD casesLogistic regressionBody mass indexRisk of coronary heart diseaseAssociated with CHD riskCase-control pairsImprove CHD risk predictionGeographically diverse populationsUntargeted metabolomicsRisk predictionFamily historyCamrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study
Ren S, Xiong A, Yu J, Wang X, Han B, Pan Y, Zhao J, Cheng Y, Hu S, Liu T, Li Y, Cheng Y, Feng J, Yi S, Gu S, Gao S, Luo Y, Liu Y, Liu C, Duan H, Wang S, Yang X, Fan J, Zhou C. Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study. Cancer Immunology, Immunotherapy 2024, 73: 124. PMID: 38727837, PMCID: PMC11087418, DOI: 10.1007/s00262-024-03715-4.Peer-Reviewed Original ResearchConceptsProgression-free survivalDisease control ratePlatinum-doublet chemotherapyOverall survivalAdvanced NSCLCCohort of advanced NSCLC patientsCombination of immune checkpoint inhibitorsMedian progression-free survivalPalmar-plantar erythrodysesthesia syndromeTreatment-related adverse eventsMedian follow-up durationFrequent grade 3Immune checkpoint inhibitorsSafety of camrelizumabTreated with camrelizumabAdvanced NSCLC patientsAdvanced solid tumorsDuration of responseDecreased neutrophil countFollow-up durationTreating multiple cancersMedian DoRCheckpoint inhibitorsMedian OSOS ratesHematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice
Chojecki A, Boselli D, Dortilus A, Hamadeh I, Begley S, Chen T, Bose R, Podoltsev N, Zeidan A, Balmaceda N, Yacoub A, Ai J, Knight T, Ragon B, Shah N, Sanikommu S, Symanowski J, Mesa R, Grunwald M. Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice. Annals Of Hematology 2024, 103: 2837-2843. PMID: 38662203, PMCID: PMC11283405, DOI: 10.1007/s00277-024-05735-7.Peer-Reviewed Original ResearchFollow-up durationPolycythemia veraThrombotic riskClinical practiceMedian follow-up durationHematocrit controlHematocrit levelsCohort study of patientsLow thrombotic riskUS Food and Drug AdministrationMonths of treatmentRisk of thrombosisStudy of patientsJanus kinase inhibitorsResponse to hydroxyureaFood and Drug AdministrationRed blood cell productionBlood cell productionCytoreductive treatmentPainful splenomegalyDose adjustmentMyeloproliferative neoplasmsPlatelet countThrombotic eventsArterial thrombosesOncogenic aberrations in primary gastric cancer tumors to predict metachronous peritoneal metastasis.
Zhao J, Huang K, Chia D, Law J, Tan A, So J, Tan P, Sundar R. Oncogenic aberrations in primary gastric cancer tumors to predict metachronous peritoneal metastasis. Journal Of Clinical Oncology 2024, 42: 392-392. DOI: 10.1200/jco.2024.42.3_suppl.392.Peer-Reviewed Original ResearchPeritoneal metastasisPrimary tumorWhole-exome sequencingARID1A mutationsGastric cancerMedian follow-up durationGS tumorsPrimary tumors of patientsMetachronous peritoneal metastasesAssociated with PMFollow-up durationGastric cancer tumorsPoor survival outcomesPrimary GC tumorsMetachronous PMAdvanced tumorsCDH1 mutationsSurgical resectionOncogenic aberrationsSurvival outcomesClinical outcomesPoor prognosisFollowed-upProspective cohortRHOA mutations
2023
Effect of retrobulbar prostaglandin analog injection on orbital fat in rats
Cosan S, İnam O, Kaya B, Atilla P, Ocal O, Arat A, Karakaya J, Arat Y. Effect of retrobulbar prostaglandin analog injection on orbital fat in rats. International Ophthalmology 2023, 43: 4985-4990. PMID: 37847476, DOI: 10.1007/s10792-023-02901-0.Peer-Reviewed Original ResearchConceptsProstaglandin analogsAdipocyte densityRetrobulbar injectionIn vivo studiesOrbital fatFat atrophySide effectsAdult male Wistar albino ratsTopical prostaglandin analogsMale Wistar albino ratsFollow-up durationControl sideInjection of PAWistar albino ratsThyroid orbitopathyLeft orbitOrbital diseaseRight orbitRat modelAnimal modelsAnalog injectionRatsImage analysis softwareImageJ image analysis softwareTreatment of diseases
2022
Association of lipid accumulation product with type 2 diabetes mellitus, hypertension, and mortality: a systematic review and meta-analysis
Khanmohammadi S, Tavolinejad H, Aminorroaya A, Rezaie Y, Ashraf H, Vasheghani-Farahani A. Association of lipid accumulation product with type 2 diabetes mellitus, hypertension, and mortality: a systematic review and meta-analysis. Journal Of Diabetes & Metabolic Disorders 2022, 21: 1943-1973. PMID: 36404835, PMCID: PMC9672205, DOI: 10.1007/s40200-022-01114-z.Peer-Reviewed Original ResearchLipid accumulation productAssociations of lipid accumulation productAll-cause mortalityType 2 diabetes mellitusAnthropometric measurementsRisk of all-cause mortalityAccumulation productConventional anthropometric indicesResultsTwenty-nine studiesStandard deviation incrementInverse variance methodCardiovascular risk assessmentWeb of ScienceCut-off pointPredicting T2DMAnthropometric indicesHazard ratioSystematic reviewEligibility criteriaMeta-analysisResultsTwenty-nineT2DMFollow-up durationMortalityAssociationAn Explainable Machine Learning Approach Reveals Prognostic Significance of Right Ventricular Dysfunction in Nonischemic Cardiomyopathy
Fahmy A, Csecs I, Arafati A, Assana S, Yankama T, Al-Otaibi T, Rodriguez J, Chen Y, Ngo L, Manning W, Kwong R, Nezafat R. An Explainable Machine Learning Approach Reveals Prognostic Significance of Right Ventricular Dysfunction in Nonischemic Cardiomyopathy. JACC Cardiovascular Imaging 2022, 15: 766-779. PMID: 35033500, DOI: 10.1016/j.jcmg.2021.11.029.Peer-Reviewed Original ResearchConceptsNonischemic dilated cardiomyopathyBeth Israel Deaconess Medical CenterComposite endpointRight ventricular (RV) dysfunctionCardiovascular hospitalizationRisk prediction modelAdverse outcomesRisk markersMarker of adverse outcomeCardiac magnetic resonance markersRisk stratification of patientsRight ventricular dysfunctionRV ejection fractionMedical CenterFollow-up durationCardiac magnetic resonanceEnd-diastolic volumeStratification of patientsArea under the curveAll-cause deathHigh-risk thresholdVentricular dysfunctionEjection fractionNonischemic cardiomyopathyPrognostic significance
2021
Transfemoral versus transapical approach for transcatheter aortic valve implantation: a systematic review and meta-analysis of adjusted studies
Hage F, Harris A, Clerc O, Altibi A, Hage A, Hamaya R, Papatheodorou S. Transfemoral versus transapical approach for transcatheter aortic valve implantation: a systematic review and meta-analysis of adjusted studies. European Heart Journal 2021, 42: ehab724.1624. DOI: 10.1093/eurheartj/ehab724.1624.Peer-Reviewed Original ResearchTranscatheter aortic valve implantationMid-term mortalityAcute kidney injuryAortic valve implantationTA-TAVIMeta-analysisKidney injuryVascular complicationsValve implantationPacemaker requirementHazard ratioOdds ratioMyocardial infarctionStandard surgical replacementHigher postoperative mortalityPostoperative aortic regurgitationAssociated with reduced vascular complicationsPerioperative surgical complicationsFollow-up durationSevere aortic stenosisKaplan-Meier curvesLong follow-upLong-term outcomesComorbidities of patientsMeta-analysis of studiesThe role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer.
Patel V, Zhong X, Shah N, Pina Martina L, Hawley J, Lin E, Gartrell B, Adorno Febles V, Wise D, Qin Q, Mellgard G, Nauseef J, Green D, Vlachostergios P, Kwon D, Huang F, Liaw B, Tagawa S, Morris M, Oh W. The role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer. Journal Of Clinical Oncology 2021, 39: 41-41. DOI: 10.1200/jco.2021.39.6_suppl.41.Peer-Reviewed Original ResearchSupplemental oxygen useNon-ADT cohortsRespiratory epithelial cellsProstate cancerOverall survivalOxygen usePC patientsFollow-upMedian duration of follow-upCohort of PC patientsCOVID-19 illnessEpithelial cellsPresence of active diseaseCourse of COVID-19 infectionDuration of follow-upCOVID-19 diagnosisAndrogen deprivation therapyClinical course of COVID-19 infectionFollow-up durationClinical follow-upMechanical ventilation requirementMultivariable mixed-effects logistic regressionCox proportionate hazard regression modelsUS medical centersSeverity of COVID-19 illness
2018
Long-term follow-up of hepatic adenoma and adenomatosis: analysis of size change on imaging with histopathological correlation
Shao N, Pandey A, Ghasabeh M, Khoshpouri P, Pandey P, Varzaneh F, Zarghampour M, Fouladi D, Pawlik T, Anders R, Kamel I. Long-term follow-up of hepatic adenoma and adenomatosis: analysis of size change on imaging with histopathological correlation. Clinical Radiology 2018, 73: 958-965. PMID: 30031588, PMCID: PMC6440203, DOI: 10.1016/j.crad.2018.06.015.Peer-Reviewed Original ResearchRadiofrequency versus Cryoballoon Ablation of Atrial Fibrillation: An Evaluation Using ECG, Holter Monitoring, and Implantable Loop Recorders to Monitor Absolute and Clinical Effectiveness
Davtyan K, Shatakhtsyan V, Poghosyan H, Deev A, Tarasov A, Kharlap M, Serdyuk S, Simonyan G, Boytcov S. Radiofrequency versus Cryoballoon Ablation of Atrial Fibrillation: An Evaluation Using ECG, Holter Monitoring, and Implantable Loop Recorders to Monitor Absolute and Clinical Effectiveness. BioMed Research International 2018, 2018: 3629384. PMID: 29721503, PMCID: PMC5867681, DOI: 10.1155/2018/3629384.Peer-Reviewed Original ResearchConceptsEfficacy end pointCryoballoon groupCryoballoon ablationRadiofrequency currentAtrial fibrillationEnd pointsClinical effectsBlanking periodSecondary efficacy end pointsAblation of atrial fibrillationNonvalvular paroxysmal AFPostablation blanking periodRate of adverse eventsFollow-up durationSafety end pointBaseline patient characteristicsTreatment of patientsLong-term efficacyLong-term outcomesImplantable loop recorderCryoballoon ablation of atrial fibrillationConsecutive patientsParoxysmal AFFollow-up methodsAsymptomatic episodes
2016
Outcomes after open infrainguinal bypass in patients with scleroderma
Arhuidese I, Malas M, Obeid T, Massada K, Khaled A, Alzahrani A, Samaha G, Reifsnyder T. Outcomes after open infrainguinal bypass in patients with scleroderma. Journal Of Vascular Surgery 2016, 64: 117-123. PMID: 27005756, DOI: 10.1016/j.jvs.2015.12.057.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAutograftsBaltimoreCritical IllnessFemaleGraft SurvivalHumansIschemiaKaplan-Meier EstimateLimb SalvageLower ExtremityMaleMiddle AgedMultivariate AnalysisPeripheral Arterial DiseaseProportional Hazards ModelsRetrospective StudiesRisk FactorsSaphenous VeinScleroderma, SystemicSeverity of Illness IndexTime FactorsTreatment OutcomeVascular GraftingVascular PatencyConceptsInfrainguinal bypass surgeryLong-term outcomesBypass surgerySystemic sclerosisGraft failureSociety for Vascular Surgery standardsScleroderma patientsArtery diseaseFollow-up durationStandard deviation ageCox regression analysisSevere peripheral arterial diseaseHistory of hypertensionLower extremity bypassCoronary artery diseaseLimb salvage rateCritical limb ischemiaPeripheral arterial diseaseDeviation ageReporting of outcomesKaplan-MeierPoor outcomeSalvage rateInfrainguinal bypassLimb ischemia
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply